A	B	C
1	Main
2		Brand Name	BMS-247550
3		Generic Name	ixabepilone
4		Indication	Metastatic Breast Cancer
5		Mechanism	Novel analog of epothilone B
6			semi-synthesis creates a minor difference
7			drug has a distinct binding mode to tubulin, may be less susceptible to resistance
8		Clinical Trials
9			p2 in indolent and mantle cell lymphoma with no more than 4 prior lines of therapy, n=18
10			qw for 3-4 wks, n=12 eval, 1 CR, 1 PR
11			significant grade 3-4 hematological toxicity
12			neutropenia and neuropathy previously seen in
13
14			Phase 3 for mBC - hoping for 2h07 filing
15			5.8m PFS for ixabepilone, 4.2m for capecitabine
16
17			trial 081 in triple refractory mBC - 18%/11% ORR - investigator/central
18			5.7 duration of response and mPFS 3.1mo, MOS 8.6mo
19			studying in RCC, CLL, prostate, pancreatic
20			325m in 2010 - b of a